Table 2A.
Inflammatory profile
| Randomization | Week 26 group differences | P‐value | ||||
|---|---|---|---|---|---|---|
| Liraglutide | Placebo | Liraglutide | Placebo | Liraglutide vs placebo | ||
| IFN‐y | 11.6 (7.6, 21.55) | 7.81 (5.42, 16.45) | 7.67 (5.96, 13.8) | 9.47 (5.21, 12.6) | −18.7% (−47.6, 26.1) | .354 |
| IL‐10 | 0.49 (0.31, 0.64) | 0.39 (0.35, 0.59) | 0.38 (0.32, 0.63) | 0.41 (0.3, 0.63) | −7.2% (−26.4, 17.0) | .528 |
| IL‐6 | 1.18 (0.73, 2.06) | 0.94 (0.79, 1.45) | 0.84 (0.64, 1.12) | 1.00 (0.79, 1.44) | −22.6% (−38.1, −3.2) | .025 |
| IL‐8 | 13.6 (11.85, 16.8) | 13.43 (11.43, 17.65) | 14.35 (10.25, 16.1) | 14.35 (12, 20.35) | −5.8% (−20.3, 11.3) | .483 |
| TNF‐a | 3.27 (3, 4.01) | 2.91 (2.67, 3.58) | 3.21 (2.95, 3.87) | 3.01 (2.64, 3.42) | 3.8% (−4.4, 12.8) | .369 |
| CD206 | 0.3 (0.23, 0.33) | 0.21 (0.18, 0.26) | 0.27 (0.25, 0.35) | 0.21 (0.19, 0.25) | −5.3% (−12.3, 2.3) | .167 |
| CD163 | 2.03 (1.63, 2.81) | 1.88 (1.5, 2.51) | 1.88 (1.6, 2.56) | 1.87 (1.58, 2.39) | −1.8% (−7.5, 4.1) | .536 |
The proinflammatory cytokines and macrophages markers in response 26 weeks of liraglutide treatment are secondary endpoints. Data are expressed as mean (standard deviation) or median and (interquartile range). Estimates of test for treatment effect are in % or absolute values (95%CL) [P values for group difference]. IFN = interferon; IL = interleukin; TNF = tumour necrosis factor; UACR = urine albumin/creatinine ratio; eGFR = estimated glomerular filtration rate. Concentration for IFN‐γ, IL‐10, IL‐6, IL‐8 and TNF‐α are pg/mL. Concentration of CD206 and CD163 are mg/L.